• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

循环肿瘤 DNA 对胰腺癌的预后价值：系统评价和荟萃分析。

Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.

机构信息

Department of Pancreatic Surgery, Fudan University Shanghai Cancer Center, Shanghai 200032, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China.

出版信息

Aging (Albany NY). 2020 Dec 9;13(2):2031-2048. doi: 10.18632/aging.202199.

DOI:10.18632/aging.202199
PMID:33318293
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7880399/
Abstract

Increasing evidence has revealed the potential correlation between circulating tumor DNA (ctDNA) and the prognosis of pancreatic cancer, but inconsistent findings have been reported. Therefore, a meta-analysis was performed to evaluate the prognostic value of ctDNA in pancreatic cancer. The Embase, MEDLINE, and Web of Science databases were searched for relevant articles published until April 2020. Articles reporting the correlation between ctDNA and the prognosis of pancreatic cancer were identified through database searches. The pooled hazard ratios (HRs) for prognostic data were calculated and analyzed using Stata software. A total of 2326 patients pooled from 25 eligible studies were included in the meta-analysis to evaluate the prognostic value of ctDNA in pancreatic cancer. Patients with mutations detected or high concentrations of ctDNA had a significantly poorer overall survival (OS) (univariate: HR = 2.54; 95% CI, 2.05-3.14; multivariate: HR = 2.07; 95% CI, 1.69-2.54) and progression-free survival (PFS) (univariate: HR = 2.18; 95% CI, 1.41-3.37; multivariate: HR = 2.20; 95% CI, 1.38-3.52). In conclusion, the present meta-analysis indicates that mutations detected or high concentrations of ctDNA are significant predictors of OS and PFS in patients with pancreatic cancer.

摘要

越来越多的证据表明循环肿瘤 DNA（ctDNA）与胰腺癌的预后之间存在潜在关联，但报道的结果并不一致。因此，进行了荟萃分析以评估 ctDNA 在胰腺癌中的预后价值。通过数据库检索，在 Embase、MEDLINE 和 Web of Science 数据库中搜索了截至 2020 年 4 月发表的相关文章。通过数据库搜索确定了报道 ctDNA 与胰腺癌预后相关性的文章。使用 Stata 软件计算并分析了用于预后数据的合并风险比（HR）。荟萃分析共纳入 25 项符合条件的研究中的 2326 例患者，以评估 ctDNA 在胰腺癌中的预后价值。检测到突变或 ctDNA 浓度较高的患者的总生存期（OS）（单变量：HR = 2.54；95%CI，2.05-3.14；多变量：HR = 2.07；95%CI，1.69-2.54）和无进展生存期（PFS）（单变量：HR = 2.18；95%CI，1.41-3.37；多变量：HR = 2.20；95%CI，1.38-3.52）显著更差。总之，本荟萃分析表明，检测到的突变或 ctDNA 浓度较高是胰腺癌患者 OS 和 PFS 的显著预测因子。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/71410c9df953/aging-13-202199-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/69d699e4efee/aging-13-202199-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/79c79dd5f332/aging-13-202199-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/10672b60f6c5/aging-13-202199-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/da5b78d66d8d/aging-13-202199-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/71410c9df953/aging-13-202199-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/69d699e4efee/aging-13-202199-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/79c79dd5f332/aging-13-202199-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/10672b60f6c5/aging-13-202199-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/da5b78d66d8d/aging-13-202199-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d3b2/7880399/71410c9df953/aging-13-202199-g005.jpg

相似文献

1
Prognostic value of circulating tumor DNA in pancreatic cancer: a systematic review and meta-analysis.循环肿瘤 DNA 对胰腺癌的预后价值：系统评价和荟萃分析。
Aging (Albany NY). 2020 Dec 9;13(2):2031-2048. doi: 10.18632/aging.202199.
2
Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer.循环核酸与胰腺癌患者的预后相关。
Gastroenterology. 2019 Jan;156(1):108-118.e4. doi: 10.1053/j.gastro.2018.09.022. Epub 2018 Sep 19.
3
Prognostic utility of preoperative and postoperative KRAS-mutated circulating tumor DNA (ctDNA) in resected pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.切除的胰腺导管腺癌术前和术后KRAS突变循环肿瘤DNA（ctDNA）的预后效用：一项系统评价和荟萃分析
Surg Oncol. 2023 Dec;51:102007. doi: 10.1016/j.suronc.2023.102007. Epub 2023 Oct 10.
4
A systematic review and meta-analysis of the association between circulating tumor DNA (ctDNA) and prognosis in pancreatic cancer.循环肿瘤 DNA（ctDNA）与胰腺癌预后相关性的系统评价和荟萃分析。
Crit Rev Oncol Hematol. 2021 Dec;168:103528. doi: 10.1016/j.critrevonc.2021.103528. Epub 2021 Nov 17.
5
Prognostic value of circulating tumour DNA in metastatic pancreatic cancer patients: post-hoc analyses of two clinical trials.循环肿瘤 DNA 对转移性胰腺癌患者预后的预测价值：两项临床试验的事后分析。
Br J Cancer. 2022 Feb;126(3):440-448. doi: 10.1038/s41416-021-01624-2. Epub 2021 Nov 22.
6
Clinical value of ctDNA in upper-GI cancers: A systematic review and meta-analysis.ctDNA 在上消化道癌症中的临床价值：系统评价和荟萃分析。
Biochim Biophys Acta Rev Cancer. 2017 Dec;1868(2):394-403. doi: 10.1016/j.bbcan.2017.08.002. Epub 2017 Aug 8.
7
Association of Circulating Tumor DNA With Disease-Free Survival in Breast Cancer: A Systematic Review and Meta-analysis.循环肿瘤 DNA 与乳腺癌无病生存的相关性：系统评价和荟萃分析。
JAMA Netw Open. 2020 Nov 2;3(11):e2026921. doi: 10.1001/jamanetworkopen.2020.26921.
8
Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.Kras 突变与循环调节性 T 细胞相关，可预测晚期胰腺癌患者的预后。
Cancer Med. 2020 Mar;9(6):2153-2159. doi: 10.1002/cam4.2895. Epub 2020 Feb 3.
9
Mutant Circulating Tumor DNA Is an Accurate Tool for Pancreatic Cancer Monitoring.循环肿瘤 DNA 突变是一种用于胰腺癌监测的精确工具。
Oncologist. 2018 May;23(5):566-572. doi: 10.1634/theoncologist.2017-0467. Epub 2018 Jan 25.
10
Circulating tumor DNA as a prognostic indicator in resectable pancreatic ductal adenocarcinoma: A systematic review and meta-analysis.循环肿瘤 DNA 作为可切除胰腺导管腺癌的预后指标：系统评价和荟萃分析。
Sci Rep. 2019 Nov 18;9(1):16971. doi: 10.1038/s41598-019-53271-6.

引用本文的文献

1
Role of m6A RNA methylation regulators in pancreatic cancer: interactions and potential implications.m6A RNA甲基化调节剂在胰腺癌中的作用：相互作用及潜在影响
Cancer Cell Int. 2025 Aug 4;25(1):292. doi: 10.1186/s12935-025-03922-8.
2
Bringing Hope to Improve Treatment in Pancreatic Ductal Adenocarcinoma-A New Tool for Molecular Profiling of Mutations in Tumor and Plasma Samples.为改善胰腺导管腺癌治疗带来希望——肿瘤和血浆样本中突变分子谱分析的新工具
Cancers (Basel). 2024 Oct 21;16(20):3544. doi: 10.3390/cancers16203544.
3
Monitoring of circulating tumour DNA in advanced pancreatic ductal adenocarcinoma predicts clinical outcome and reveals disease progression earlier than radiological imaging.

本文引用的文献

1
A Multianalyte Panel Consisting of Extracellular Vesicle miRNAs and mRNAs, cfDNA, and CA19-9 Shows Utility for Diagnosis and Staging of Pancreatic Ductal Adenocarcinoma.一个由细胞外囊泡 miRNA 和 mRNA、cfDNA 和 CA19-9 组成的多分析物panel 可用于胰腺导管腺癌的诊断和分期。
Clin Cancer Res. 2020 Jul 1;26(13):3248-3258. doi: 10.1158/1078-0432.CCR-19-3313. Epub 2020 Apr 16.
2
Kras mutation correlating with circulating regulatory T cells predicts the prognosis of advanced pancreatic cancer patients.Kras 突变与循环调节性 T 细胞相关，可预测晚期胰腺癌患者的预后。
Cancer Med. 2020 Mar;9(6):2153-2159. doi: 10.1002/cam4.2895. Epub 2020 Feb 3.
3
在晚期胰腺导管腺癌中监测循环肿瘤 DNA 可预测临床结局，并比影像学更早地揭示疾病进展。
Mol Oncol. 2023 Sep;17(9):1857-1870. doi: 10.1002/1878-0261.13472. Epub 2023 Jun 28.
4
Circulating Cell-Free Nucleic Acids as Biomarkers for Diagnosis and Prognosis of Pancreatic Cancer.循环游离核酸作为胰腺癌诊断和预后的生物标志物
Biomedicines. 2023 Apr 1;11(4):1069. doi: 10.3390/biomedicines11041069.
5
Analysis of Risk Factors for Distant Metastasis of Pancreatic Ductal Adenocarcinoma without Regional Lymph Node Metastasis and a Nomogram Prediction Model for Survival.无区域淋巴结转移的胰腺导管腺癌远处转移危险因素分析及生存列线图预测模型
Evid Based Complement Alternat Med. 2023 Feb 21;2023:2916974. doi: 10.1155/2023/2916974. eCollection 2023.
6
The current state of molecular profiling in gastrointestinal malignancies.胃肠恶性肿瘤中分子谱分析的现状。
Biol Direct. 2022 Jun 6;17(1):15. doi: 10.1186/s13062-022-00322-0.
7
Construction of a five-gene prognostic model based on immune-related genes for the prediction of survival in pancreatic cancer.构建基于免疫相关基因的五个基因预后模型，用于预测胰腺癌的生存情况。
Biosci Rep. 2021 Jul 30;41(7). doi: 10.1042/BSR20204301.
8
Circulating Tumor DNA Detection by Digital-Droplet PCR in Pancreatic Ductal Adenocarcinoma: A Systematic Review.数字液滴PCR检测胰腺导管腺癌循环肿瘤DNA的系统评价
Cancers (Basel). 2021 Feb 27;13(5):994. doi: 10.3390/cancers13050994.
Preoperative detection of KRAS G12D mutation in ctDNA is a powerful predictor for early recurrence of resectable PDAC patients.
ctDNA 中 KRAS G12D 突变的术前检测是可切除 PDAC 患者早期复发的有力预测指标。
Br J Cancer. 2020 Mar;122(6):857-867. doi: 10.1038/s41416-019-0704-2. Epub 2020 Jan 23.
4
Cancer statistics, 2020.癌症统计数据，2020 年。
CA Cancer J Clin. 2020 Jan;70(1):7-30. doi: 10.3322/caac.21590. Epub 2020 Jan 8.
5
Longitudinal monitoring of KRAS-mutated circulating tumor DNA enables the prediction of prognosis and therapeutic responses in patients with pancreatic cancer.对 KRAS 突变的循环肿瘤 DNA 进行纵向监测可预测胰腺癌患者的预后和治疗反应。
PLoS One. 2019 Dec 31;14(12):e0227366. doi: 10.1371/journal.pone.0227366. eCollection 2019.
6
Clinical correlates of blood-derived circulating tumor DNA in pancreatic cancer.胰腺癌血液衍生循环肿瘤 DNA 的临床相关性。
J Hematol Oncol. 2019 Dec 4;12(1):130. doi: 10.1186/s13045-019-0824-4.
7
Analysis of circulating cell-free DNA identifies KRAS copy number gain and mutation as a novel prognostic marker in Pancreatic cancer.循环无细胞 DNA 分析鉴定 KRAS 拷贝数增益和突变作为胰腺癌的一种新的预后标志物。
Sci Rep. 2019 Aug 12;9(1):11610. doi: 10.1038/s41598-019-47489-7.
8
Circulating tumor DNA quantity is related to tumor volume and both predict survival in metastatic pancreatic ductal adenocarcinoma.循环肿瘤 DNA 量与肿瘤体积有关，两者均可预测转移性胰腺导管腺癌的生存情况。
Int J Cancer. 2020 Mar 1;146(5):1445-1456. doi: 10.1002/ijc.32586. Epub 2019 Aug 13.
9
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.循环肿瘤 DNA 作为局部胰腺癌手术后辅助化疗获益的潜在标志物。
Ann Oncol. 2019 Sep 1;30(9):1472-1478. doi: 10.1093/annonc/mdz200.
10
Liquid biopsy in pancreatic ductal adenocarcinoma: current status of circulating tumor cells and circulating tumor DNA.胰腺导管腺癌的液体活检：循环肿瘤细胞和循环肿瘤 DNA 的现状。
Mol Oncol. 2019 Aug;13(8):1623-1650. doi: 10.1002/1878-0261.12537. Epub 2019 Jul 30.